Driehaus Capital Management Reduces $15M in Septerna, Inc. ($SEPN)
Key Points
- Driehaus Capital Management changed its Septerna, Inc. ($SEPN) stake by 8.6% last quarter, cutting to 4,395,572 shares worth $158.02 million.
- Wall Street's consensus rating on $SEPN is Strong Buy and an average price target of $45.78.
- $SEPN last traded around $35.95.
Driehaus Capital Management trimmed its position in Septerna, Inc. ($SEPN) by 8.6% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,395,572 shares of Septerna, Inc. after selling 413,898 shares during the quarter. Driehaus Capital Management's holdings in Septerna, Inc. were worth $158.02 million as of its most recent filing.
Septerna, Inc. ($SEPN) Stock
Septerna, Inc. Earnings
Analysts Set New Price Targets
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.